Encontrados 5 documentos, a visualizar página 1 de 1
Transitioning intravenous epoprostenol to oral selexipag in idiopathic pulmonar...
Alexandre, André; Furtado, Inês; Gonçalves, Fabienne; Gonçalves, Fabienne; Melo, Alzira; Alves, Joana; Santos, Mario; Reis, AbilioIntravenous (i.v.) prostacyclin is the cornerstone treatment in high-risk pulmonary arterial hypertension (PAH) patients. Selexipag is an orally available prostacyclin receptor agonist. Limited data are available regarding the feasibility of transitioning from i.v. epoprostenol to selexipag. A 50-year-old woman with idiopathic PAH was diagnosed in a World Health Organization (WHO) Functional Class (FC) IV. She ...
PH CARE COVID survey: an international patient survey on the care for pulmonary...
Godinas, Laurent; Iyer, Keerthana; Meszaros, Gergely; Quarck, Rozenn; Escribano-Subias, Pilar; Vonk Noordegraaf, Anton; Jansa, Pavel; D’Alto, MicheleBackground: During the COVID-19 pandemic, most of the health care systems suspended their non-urgent activities. This included the cancellation of consultations for patients with rare diseases, such as severe pulmonary hypertension (PH), resulting in potential medication shortage and loss of follow-up. Thus, the aim of the study was to evaluate PH patient health status evolution, access to health care and menta...
Association Between Preexisting Versus Newly Identified Atrial Fibrillation and...
Bikdeli, Behnood; Jiménez, David; del Toro, Jorge; Piazza, Gregory; Rivas, Agustina; Fernández‐Reyes, José Luis; Sampériz, Ángel; Otero, RemediosBackground Atrial fibrillation (AF) may exist before or occur early in the course of pulmonary embolism (PE). We determined the PE outcomes based on the presence and timing of AF. Methods and Results Using the data from a multicenter PE registry, we identified 3 groups: (1) those with preexisting AF, (2) patients with new AF within 2 days from acute PE (incident AF), and (3) patients without AF. We assessed the...
Severe Pulmonary Hypertension Management Across Europe (PHAROS): an ERS Clinica...
Sitbon, Olivier; Reis, Abilio; Humbert, Marc; Vonk Noordegraaf, Anton; Delcroix, MarionThe overall objective of the PHAROS CRC is to establish a platform for clinical research in pulmonary hypertension, in close collaboration with the ERN-Lung, able to coordinate future collaborative research in Europe https://bit.ly/2Rx2FTl
Pulmonary arterial hypertension registries: past, present and into the future
Weatherald, J.; Reis, Abilio; Sitbon, O.; Humbert, M.Registries have greatly contributed to knowledge about PAH epidemiology, risk factors, prognosis and treatment. Future registries face unique challenges but may benefit from integration of multiple data sources and capitalising on “Big Data” opportunities